Compare AbCellera Biologics Inc (ABCL) vs Comcast Corporation (CMCSA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Comcast Corporation — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while Comcast Corporation trades at $23.59 (market cap $83.63B). The key difference: Comcast Corporation is far larger — about 35.6× AbCellera Biologics Inc's market cap, and Comcast Corporation pays a 5.64% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | CMCSA | |
|---|---|---|
Market Cap | $2.35B | $83.63B |
Sector | Health | Media |
52-Week High | $8.12 | $34.01 |
52-Week Low | $2.78 | $22.32 |
Enterprise Value | $1.99B | $168.77B |
Dividend Yield | — | 5.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
CMCSA trades at $23.41, down 1.6% over 24 hours, with a bearish technical signal but strong fundamentals including a low P/E of 4.66 and net income margin of 15%. Recent news highlights the planned spin-off of NBCUniversal and Sky's acquisition of ITV's media unit for $2.14 billion, signaling strategic refocusing on broadband infrastructure.
The stock appears undervalued with a consensus price target of $31.07, offering 33% upside, but faces risks from execution of corporate restructuring and pay-TV decline. Positive earnings beats and robust cash flow support a favorable outlook, though investor sentiment is mixed amid spin-off uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →
